COVID-19 has brought the healthcare sector into sharp focus, driving and in some cases accelerating demand for products and services. At the same time, we believe valuations are extremely compelling while we have only just begun to see a change in sector leadership. Blue chip companies, with their defensive, sustainable growth and strong balance sheets and cash-flows, are uniquely positioned to benefit, with five factors supporting the sector.